在17个月内开发Nirmatrelvir的商业制造工艺
Christophe Allais1, Christina G Connor1, Nga M Do1
1Pfizer Worldwide Research & Development, Chemical Research & Development, Groton, Connecticut 06355, United States.
ACS central science
|May 30, 2023
概括
帕克斯洛维德的活性成分尼尔马特雷尔维尔在创纪录的17个月内获得了紧急使用许可. 这种快速的进步凸显了抗病毒药物的化学工艺开发前所未有的步伐.
科学领域:
- 制药化学 制药化学 的相关文章
- 药物开发 药物开发
- 过程化学 过程化学
背景情况:
- 帕克斯洛维德的关键成分尼马特里尔维尔的开发时间表被压缩成从最初的发现到紧急使用授权的非凡17个月.
- 这种加速的途径需要一个高效和快速的化学工艺开发战略.
更多相关视频
18:46Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
13.4K
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.3K
相关概念视频
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
